Table 4.
ANSS and ATSS for subjects with symptoms of common cold (study 2)
| Efficacy endpoint | Parameter | 0.5% Carbomer 980 gel nasal spray (n = 86) | Placebo nasal spray (n = 79) | Difference (95% CI) in LS means; p value |
|---|---|---|---|---|
| ANSS1-4 | Mean ± SD | 3.43 ± 1.48 | 3.34 ± 1.69 | NA |
| Median (range) | 3.22 (0.46–7.56) | 3.00 (0.31–9.00) | NA | |
| LS mean | 3.781 | 3.644 | 0.137 (− 0.279 to − 0.533); 0.516 | |
| ANSS1–7 | Mean ± SD | 2.70 ± 1.31 | 2.65 ± 1.55 | NA |
| Median (range) | 2.44 (0.26–6.39) | 2.37 (0.18–8.36) | NA | |
| LS mean | 2.985 | 2.877 | 0.108 (− 0.292 to − 0.507); 0.595 | |
| ATSS1–4 | Mean ± SD | 7.81 ± 3.20 | 7.75 ± 3.50 | NA |
| Median (range) | 7.53 (1.73–17.29) | 7.31 (2.75–20.31) | NA | |
| LS mean | 8.352 | 8.304 | 0.048 (− 0.809 to − 0.906); 0.911 | |
| ATSS1–7 | Mean ± SD | 6.17 ± 2.98 | 6.20 ± 3.21 | NA |
| Median (range) | 5.64 (1.63–16.00) | 5.50 (1.57–18.25) | NA | |
| LS mean | 6.647 | 6.613 | 0.034 (− 0.834 to − 0.902); 0.938 |
ANSSx–x average nasal symptom score over days x–x, ATSSx–x average total symptom score, CI confidence interval, LS least square, NA not applicable, SD standard deviation